Safety Study of CTS21166 to Treat Alzheimer Disease

A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males

This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers

Inclusion Criteria:

• Healthy adult male > age 21;
• non-smoker (minimum 6 months);

Exclusion Criteria:

• History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease
• History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
• Participation in another clinical trial within 30 days prior to dosing